GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearside Biomedical Inc (NAS:CLSD) » Definitions » Cyclically Adjusted PB Ratio

Clearside Biomedical (Clearside Biomedical) Cyclically Adjusted PB Ratio : 1.69 (As of Jun. 10, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Clearside Biomedical Cyclically Adjusted PB Ratio?

As of today (2024-06-10), Clearside Biomedical's current share price is $1.215. Clearside Biomedical's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $0.72. Clearside Biomedical's Cyclically Adjusted PB Ratio for today is 1.69.

The historical rank and industry rank for Clearside Biomedical's Cyclically Adjusted PB Ratio or its related term are showing as below:

CLSD' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.69   Med: 1.82   Max: 1.94
Current: 1.7

During the past years, Clearside Biomedical's highest Cyclically Adjusted PB Ratio was 1.94. The lowest was 1.69. And the median was 1.82.

CLSD's Cyclically Adjusted PB Ratio is ranked worse than
50.23% of 661 companies
in the Biotechnology industry
Industry Median: 1.67 vs CLSD: 1.70

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Clearside Biomedical's adjusted book value per share data for the three months ended in Mar. 2024 was $-0.292. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.72 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Clearside Biomedical Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Clearside Biomedical's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearside Biomedical Cyclically Adjusted PB Ratio Chart

Clearside Biomedical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Clearside Biomedical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 2.14

Competitive Comparison of Clearside Biomedical's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Clearside Biomedical's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clearside Biomedical's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearside Biomedical's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Clearside Biomedical's Cyclically Adjusted PB Ratio falls into.



Clearside Biomedical Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Clearside Biomedical's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.215/0.72
=1.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clearside Biomedical's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Clearside Biomedical's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.292/131.7762*131.7762
=-0.292

Current CPI (Mar. 2024) = 131.7762.

Clearside Biomedical Quarterly Data

Book Value per Share CPI Adj_Book
201312 -0.554 98.326 -0.742
201409 0.000 100.428 0.000
201412 -1.565 99.070 -2.082
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 -0.353 100.392 -0.463
201512 -2.256 99.792 -2.979
201603 0.336 100.470 0.441
201606 2.342 101.688 3.035
201609 2.285 101.861 2.956
201612 2.916 101.863 3.772
201703 2.655 102.862 3.401
201706 2.144 103.349 2.734
201709 1.456 104.136 1.842
201712 0.845 104.011 1.071
201803 2.690 105.290 3.367
201806 2.082 106.317 2.581
201809 1.376 106.507 1.702
201812 0.735 105.998 0.914
201903 0.437 107.251 0.537
201906 0.342 108.070 0.417
201909 0.237 108.329 0.288
201912 0.251 108.420 0.305
202003 0.233 108.902 0.282
202006 0.157 108.767 0.190
202009 0.168 109.815 0.202
202012 0.169 109.897 0.203
202103 0.295 111.754 0.348
202106 0.327 114.631 0.376
202109 0.299 115.734 0.340
202112 0.636 117.630 0.712
202203 0.527 121.301 0.573
202206 0.420 125.017 0.443
202209 0.308 125.227 0.324
202212 0.175 125.222 0.184
202303 0.044 127.348 0.046
202306 -0.081 128.729 -0.083
202309 -0.207 129.860 -0.210
202312 -0.253 129.419 -0.258
202403 -0.292 131.776 -0.292

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Clearside Biomedical  (NAS:CLSD) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Clearside Biomedical Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Clearside Biomedical's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Clearside Biomedical (Clearside Biomedical) Business Description

Traded in Other Exchanges
Address
900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
Executives
Charles A. Deignan officer: Chief Financial Officer C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005
George M Lasezkay director 1301 SECOND AVE., SUITE 4200, SEATTLE WA 98101
Bradford T Whitmore 10 percent owner 5215 OLD ORCHARD ROAD, SUITE 620, SKOKIE IL 60077
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Clay Thorp director, 10 percent owner C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701
Thomas Ciulla officer: Chief Medical Officer C/O CLEARSIDE BIOMEDICAL, INC., 900 NORTH POINT PARKWAY, SUITE 200, ALPHARETTA GA 30005
Benjamin R Yerxa director INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466
William D. Humphries director C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Jeffrey L Edwards director 2525 DUPONT DR, IRVINE CA 92612
Daniel H. White director, officer: President and CEO C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005
Gerald D. Cagle director 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Brion S. Raymond officer: Chief Commercial Officer C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005
Christy L Shaffer director INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466
Hatteras Venture Advisors Iv Sbic, Llc 10 percent owner 280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701
Hatteras Venture Advisors Iii, Llc 10 percent owner 280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701

Clearside Biomedical (Clearside Biomedical) Headlines

From GuruFocus